1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (713) 792-7586
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium
Article first published online: 25 JUN 2003
DOI: 10.1002/cncr.11561
Copyright © 2003 American Cancer Society
Additional Information
How to Cite
Schmandt, R. E., Broaddus, R., Lu, K. H., Shvartsman, H., Thornton, A., Malpica, A., Sun, C., Bodurka, D. C. and Gershenson, D. M. (2003), Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer, 98: 758–764. doi: 10.1002/cncr.11561
Publication History
- Issue published online: 1 AUG 2003
- Article first published online: 25 JUN 2003
- Manuscript Accepted: 7 MAY 2003
- Manuscript Revised: 2 MAY 2003
- Manuscript Received: 24 JAN 2003
Funded by
- M. D. Anderson Blanton-David Ovarian Cancer Research Program
- Beth Liebman and the Elizabeth Fund
- Ovarian Cancer Research Fund
REFERENCES
- 1American Cancer Society. Cancer facts and figures 2003 [monograph online]. Available from URL: http://www.cancer.org/docroot/STT/stt_0.asp or URL: http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf
- 2, , , . Cancer statistics, 2002. CA Cancer J Clin. 2002; 52: 23–47.Direct Link:
- 3. Surgical management of ovarian cancer. Semin Oncol. 2002; 29: 3–8.
- 4, . Part I: chemotherapy for epithelial ovarian cancer—treatment at first diagnosis. Lancet Oncol. 2002; 3: 529–536.
- 5, . Part II: chemotherapy for epithelial ovarian cancer—treatment of recurrent disease. Lancet Oncol. 2002; 3: 537–545.
- 6
- 7. Current clinical practices for ovarian cancers. Semin Oncol. 2002; 29: 3–6.
- 8. Future directions in the treatment of ovarian cancer. Semin Oncol. 2002; 29: 32–42.
- 9, , . The protein tyrosine kinase family of the human genome. Oncogene. 2000; 19: 5548–5557.
- 10, . The hallmarks of cancer. Cell. 2000; 100: 57–70.
- 11, . Oncogenic kinase signaling. Nature. 2001; 411: 355–365.
- 12, . Protein tyrosine kinases and cancer. Biochim Biophys Acta. 1997; 1333: F217-F248.
- 13. Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Genet Dev. 2002; 12: 111–115.
- 14, , . Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med. 2002; 8: 17–23.
- 15, , . Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002; 1: 117–123.
- 16, . Development of inhibitors for protein tyrosine kinases. Oncogene. 2000; 19: 5690–5701.
- 17, , , et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther. 2002; 93: 79–98.
- 18. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med. 2002; 8: S14–S18.
- 19, , , . Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002; 1: 493–502.
- 20
- 21, , . Recent advancements in the treatment of chronic myelogenous leukemia. Annu Rev Med. 2002; 53: 369–381.
- 22, , , et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472–480.
- 23. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol. 2002; 9: 831–839.
- 24. An overview of translocation-related oncogenesis in the chronic myeloid leukaemias. Acta Haematol. 2002; 107: 57–63.
- 25, , , et al. Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis. Am J Pathol. 2002; 161: 781–786.
- 26, , , , . PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol. 1994; 125: 917–928.
- 27, , , , , . Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. J Mol Neurosci. 1999; 13: 177–185.
- 28, , , et al. Grading ovarian serous carcinoma using a two-tier system. Mod Pathol. 2002; 15: 202A–203A.
- 29, . Abl: mechanisms of regulation and activation. Front Biosci. 2002; 7: d31–d42.
- 30, . Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J Biol Chem. 1999; 274: 18141–18144.
- 31, , , . Abl expression in human fetal and adult tissues, tumours, and tumour microvessels. J Pathol. 1997; 183: 325–329.Direct Link:
- 32, . Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999; 79: 1283–1316.
- 33, , . Developmental roles of platelet-derived growth factors. Bioessays. 2001; 23: 494–507.Direct Link:
- 34. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol. 2001; 28: 27–33.
- 35, , , et al. Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. Cancer Genet Cytogenet. 1994; 73: 60–64.
- 36, , , . The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol. 1998; 71: 29–37.
- 37, , , , , . Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 1993; 53: 4550–4554.
- 38, , , . Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002; 20: 1692–1703.
- 39, , , . Germ cell specific expression of c-KIT in the human fetal gonad. Mol Hum Reprod. 2001; 7: 845–852.
- 40, , , . Roles of KIT and KIT LIGAND in ovarian function. Rev Reprod. 2000; 5: 143–152.
- 41, . Cellular interactions that control primordial follicle development and folliculogenesis. J Soc Gynecol Investig. 2001; 8: S17–S20.
- 42. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol. 2001; 28: 19–26.
- 43, , . Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod. 2000; 62: 1600–1609.
- 44, , , . Autocrine interactions of keratinocyte growth factor, hepatocyte growth factor, and KIT-ligand in the regulation of normal ovarian surface epithelial cells. Endocrinology. 2000; 141: 2532–2539.
- 45, , , , . Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer. 2000; 89: 242–250.Direct Link:
- 46, , . Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol. 1998; 29: 498–504.
- 47, , , , . c-kit receptors in ovarian tumors and the response of ovarian carcinoma cell lines to recombinant human stem cell factor. Int J Gynecol Cancer. 1996; 6: 273–278.Direct Link:
- 48, , , , . Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 1994; 54: 3049–3053.